392 related articles for article (PubMed ID: 32440182)
1. Familial Partial Lipodystrophy (FPLD): Recent Insights.
Bagias C; Xiarchou A; Bargiota A; Tigas S
Diabetes Metab Syndr Obes; 2020; 13():1531-1544. PubMed ID: 32440182
[TBL] [Abstract][Full Text] [Related]
2. Familial partial lipodystrophy syndromes.
Fernández-Pombo A; Sánchez-Iglesias S; Cobelo-Gómez S; Hermida-Ameijeiras Á; Araújo-Vilar D
Presse Med; 2021 Nov; 50(3):104071. PubMed ID: 34610417
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
4. Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?
Vatier C; Vigouroux C; Mosbah H
Ann Endocrinol (Paris); 2024 Jun; 85(3):190-194. PubMed ID: 38871502
[TBL] [Abstract][Full Text] [Related]
5. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E
Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
Foss-Freitas MC; Akinci B; Neidert A; Bartlett VJ; Hurh E; Karwatowska-Prokopczuk E; Oral EA
Lipids Health Dis; 2021 Dec; 20(1):174. PubMed ID: 34865644
[TBL] [Abstract][Full Text] [Related]
7. Leptin replacement therapy in the management of lipodystrophy syndromes.
Vigouroux C; Mosbah H; Vatier C
Ann Endocrinol (Paris); 2024 Jun; 85(3):201-204. PubMed ID: 38871500
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.
Park JY; Javor ED; Cochran EK; DePaoli AM; Gorden P
Metabolism; 2007 Apr; 56(4):508-16. PubMed ID: 17379009
[TBL] [Abstract][Full Text] [Related]
9. Lipodystrophy for the Diabetologist-What to Look For.
Patni N; Garg A
Curr Diab Rep; 2022 Sep; 22(9):461-470. PubMed ID: 35821558
[TBL] [Abstract][Full Text] [Related]
10. Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in
Rutkowska L; Salachna D; Lewandowski K; Lewiński A; Gach A
Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626278
[TBL] [Abstract][Full Text] [Related]
11. Lipodystrophy Syndromes.
Hussain I; Garg A
Endocrinol Metab Clin North Am; 2016 Dec; 45(4):783-797. PubMed ID: 27823605
[TBL] [Abstract][Full Text] [Related]
12. [Primary lipodystrophies].
Capeau J; Magré J; Lascols O; Caron M; Béréziat V; Vigouroux C
Ann Endocrinol (Paris); 2007 Feb; 68(1):10-20. PubMed ID: 17320032
[TBL] [Abstract][Full Text] [Related]
13. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies.
Nolis T
J Hum Genet; 2014 Jan; 59(1):16-23. PubMed ID: 24152769
[TBL] [Abstract][Full Text] [Related]
14. Atypical generalized lipoatrophy and severe insulin resistance due to a heterozygous LMNA p.T10I mutation.
Mory PB; Crispim F; Kasamatsu T; Gabbay MA; Dib SA; Moisés RS
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1252-6. PubMed ID: 19169477
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
[TBL] [Abstract][Full Text] [Related]
16. Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome.
Guillín-Amarelle C; Sánchez-Iglesias S; Castro-Pais A; Rodriguez-Cañete L; Ordóñez-Mayán L; Pazos M; González-Méndez B; Rodríguez-García S; Casanueva FF; Fernández-Marmiesse A; Araújo-Vilar D
Endocrine; 2016 Nov; 54(2):411-421. PubMed ID: 27473102
[TBL] [Abstract][Full Text] [Related]
17. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
18. Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism.
Hegele RA; Joy TR; Al-Attar SA; Rutt BK
J Lipid Res; 2007 Jul; 48(7):1433-44. PubMed ID: 17374881
[TBL] [Abstract][Full Text] [Related]
19. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.
Hussain I; Patni N; Garg A
Pathology; 2019 Feb; 51(2):202-212. PubMed ID: 30595509
[TBL] [Abstract][Full Text] [Related]
20. Lipodystrophies in Children.
Mainieri F; Chiarelli F
Horm Res Paediatr; 2022; 95(4):305-320. PubMed ID: 35189617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
